CD Biosynsis delivers comprehensive Genome Editing and Metabolic Engineering Solutions tailored for Corynebacterium glutamicum, the premier industrial host for producing amino acids (e.g., L-lysine, L-glutamate) and various fine chemicals. Our integrated services cover the entire development lifecycle, from precise genetic modification to pathway optimization and high-throughput strain screening. By leveraging advanced tools like optimized CRISPR-Cas9, state-of-the-art computational modeling, and robust analytical assays, we eliminate bottlenecks and maximize the production efficiency of your target compounds. Partner with us to accelerate your bioproduction R&D and achieve superior industrial strains.
Get a QuoteThe successful optimization of $C. glutamicum$ for industrial production requires a synergistic approach combining genetic precision with data-driven insights. Our platform is built upon a foundation of proprietary Cas9 systems and deep metabolic expertise. We move beyond simple gene editing, providing tools for complex pathway balancing, regulatory control, and rigorous performance validation. This holistic strategy minimizes trial-and-error, ensuring that every modification—from single point mutation to multi-gene knockout—is rationally designed and validated against industrial metrics, guaranteeing reliable and stable high-yield strains for commercial use.
Core platform for rapid and high-efficiency insertion, deletion, and precision mutation.
Targeted elimination of competing genes or stable integration of heterologous pathways.
Reversible silencing of essential or regulatory genes without permanent genome alteration for functional studies.
High-fidelity single base pair substitutions to optimize enzyme activity or promoter strength.
Simultaneous deletion of multiple target genes to construct complex metabolic chassis strains in one step.
Balancing enzyme expression, promoter tuning, and host integration to maximize flux through novel pathways.
Integrated HTS and fermentation validation to rapidly select the best performing production strains.
Production and purification of target enzymes or regulatory proteins using the $C. glutamicum$ host system.
Leveraging 13C-MFA and Genome-Scale Models (GEMs) to identify bottlenecks and predict optimal genetic targets.
Our systematic Design-Build-Test-Analyze (DBTA) cycle ensures accelerated project success.
1. Design (Modeling & Analysis)
2. Build (Genetic Editing)
3. Test (Screening & Validation)
4. Analyze (QC & Data Interpretation)
Utilize predictive GEMs and 13C-MFA data to identify key target genes for modification.
Define the optimal strategy: knockout, knock-in, point mutation, or multiplexing.
Bioinformatic design of sgRNA, donor DNA, and expression cassettes.
High-efficiency construction of engineered $C. glutamicum$ strains using optimized CRISPR-Cas9 systems.
Creation of mutant libraries or precise single-strain modifications.
Implementation of marker-free and plasmid-curing protocols.
Automated High-Throughput Screening (HTS) to quickly assess the performance of hundreds of clones.
Small-scale bioreactor validation to confirm performance under industrial fermentation conditions.
Phenotypic characterization (growth rate, product titer, yield).
Rigorous genetic verification (Sanger Sequencing/PCR) for $100\%$ fidelity.
Metabolomics and flux analysis (optional) to close the DBTA loop and guide the next optimization round.
Delivery of verified strains and comprehensive Certificate of Analysis (CoA).
Integrated DBTA Platform
A seamless cycle that links computational design with precision genetic building and rigorous analytical testing, ensuring rapid optimization.
Multiplex Editing Efficiency
Proprietary CRISPR-Cas9 systems capable of simultaneous multi-gene knockouts to accelerate complex chassis strain construction.
Metabolic Expertise
Deep knowledge of $C. glutamicum$ central metabolism, particularly for amino acid pathways, to ensure rational and impactful target selection.
Industrial Validation
Standardized HTS and small-scale bioreactor validation protocols to guarantee that laboratory performance translates reliably to industrial scale.
"The integrated modeling and editing services allowed us to finalize our L-glutamate production strain in half the projected time, thanks to the accurate prediction of the key bottleneck."
Dr. Lee, VP of R&D, Bioproduction Firm
"The multiplex knockout service was a game-changer, providing a clean, marker-free chassis ready for the large-scale integration of our synthetic pathway."
Mr. Alex Johnson, Bioengineering Lead, Specialty Chemicals
"The HTS and bioreactor validation confirmed the strain's robustness before we committed to pilot scale, saving us significant resources and time."
Dr. Maria Perez, Fermentation Director, Industrial Microbiology
What is the key advantage of using $C. glutamicum$ for bioproduction?
$C. glutamicum$ is non-pathogenic, secretes target amino acids efficiently, and possesses robust central metabolic pathways, making it an ideal, globally accepted host for large-scale industrial fermentation.
How does the integrated DBTA cycle accelerate strain development?
By integrating predictive modeling (Design) and analytical feedback (Analyze) with rapid editing (Build) and HTS (Test), we minimize empirical testing, ensuring that only the most rational and impactful genetic modifications are pursued.
Do you offer marker-free and genetically stable strains?
Yes. All final production strains are rigorously processed to remove antibiotic resistance markers and the Cas9 expression plasmid, guaranteeing a clean and stable genome for regulatory compliance and long-term industrial use.
Can you handle complex projects involving heterologous pathway integration?
Absolutely. Our Gene Knock-in services are optimized for the stable chromosomal integration of large DNA fragments, including entire heterologous biosynthetic pathways, into safe harbor loci within the $C. glutamicum$ genome.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.